Neuronal acetylcholine receptor subunit alpha-7 (CHRNA7) (CHRNA7)

The neuronal acetylcholine receptor subunit alpha-7 (CHRNA7) is a homopentameric ligand-gated ion channel that plays a critical role in the central nervous system and the peripheral immune system. It is distinguished by its high permeability to calcium ions and its rapid desensitization kinetics upon activation by acetylcholine or nicotine [1]. In the brain, alpha-7 receptors are highly expressed in the hippocampus and cerebral cortex, where they modulate neurotransmitter release and facilitate long-term potentiation, making them vital for learning, memory, and sensory gating [2]. Dysregulation of this receptor is strongly linked to the pathophysiology of schizophrenia and Alzheimer's disease, particularly regarding cognitive deficits [3]. Beyond the CNS, the alpha-7 receptor is a key component of the cholinergic anti-inflammatory pathway, where its activation on macrophages inhibits the release of pro-inflammatory cytokines [4]. Therapeutic strategies targeting CHRNA7 include full and partial agonists, as well as positive allosteric modulators, aimed at treating cognitive impairment and chronic inflammatory conditions [5]. These drugs seek to enhance synaptic plasticity and reduce neuroinflammation by fine-tuning the receptor's activity [6]. However, the rapid desensitization of the receptor remains a significant challenge in drug development, often requiring precise dosing or allosteric approaches [7].

Other names

Alpha-7 nicotinic receptorNicotinic acetylcholine receptor subunit alpha-7nAChR alpha-7Cholinergic receptor nicotinic alpha 7 subunit

Agonism, partial agonism, or positive allosteric modulation to enhance channel opening and calcium influx.